Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
11 evidence topics · 17 sources
Management in designated referral centers with a multidisciplinary tumor board
“Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A multidisciplinary discussion in soft tissue tumor boards is necessary to propose a personalized management; furthermore, a discussion with the patient is also necessary for tailoring this proposal to its objectives given the natural course of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second opinion by an expert pathologist as well as clinical management by an expert team is highly recommended” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcomas and the Desmoid Tumor Working Group (DTWG) Global Consensus Paper Guidelines state that diagnosis and treatment be informed and supported by a multidisciplinary team” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Supportive care, pregnancy, and family planning
“Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring requirements in the approved gamma secretase inhibitor label
Diarrhea management with nirogacestat in oncology practices
Ovarian toxicity monitoring and fertility counseling
“Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment; of these, all nine with available menstruation information experienced return of menstruation and eight had FSH WNL at last reported assessment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visit and laboratory frequency during nirogacestat treatment
Dose modification to maintain gamma secretase inhibitor treatment
“Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Onset of adverse events with varegacestat in RINGSIDE Part B
| Adverse event (varegacestat, N=79) | All grades, n (%) | Median time to onset (days) |
|---|---|---|
| Diarrhea | “65 (82.3)” | “14.0” |
| Nausea | “28 (35.4)” | “8.0” |
| Rash | “56 (70.9)” | “24.0” |
| Fatigue | “46 (58.2)” | “27.5” |
| Hypophosphatemia | “27 (34.2)” | “29.0” |
| Ovarian toxicity | “20 (25.3)” | “56.5” |
Commercial payer prior authorization criteria for nirogacestat
State Medicaid prior authorization criteria for nirogacestat and new antineoplastics
“LENGTH OF AUTHORIZATION: Varies; Maximum of one year” (opens the source at this quote in a new tab)
“60 per 30 days (100mg and 150mg)” (opens the source at this quote in a new tab)